Immune reconstitution inflammatory syndrome-associated lymphoma: A retrospective Brazilian cohort.
Juliano Córdova VargasKarin Zattar CecynMariana de Oliveira MarquesJuliana PereiraWalter M Tobias BragaNelson HamerschlakJacques TabacofCaina D de LizAndré AbdoPaulo Roberto Abrão FerreiraGisele W Braga ColleoniOtavio C G BaiocchiPublished in: EJHaem (2023)
After initiating combined antiretroviral therapy (cART), individuals with human immunodeficiency virus (HIV) may develop Hodgkin/non-Hodgkin lymphoma due to immune reconstitution inflammatory syndrome (IRIS). This retrospective cohort study evaluated the incidence, clinical features and prognosis of IRIS-associated lymphomas in Brazilian patients. Incidence in 2000-2019 was 9.8% (27/276 patients with HIV and lymphoma; viral load drop >1 log). Time between HIV diagnosis and cART initiation was <1 year in 70.3% of cases. Time between cART initiation and lymphoma diagnosis was <3 months in 11 cases and 3-6 months in 16 cases. Overall and progression-free survival rates were similar between cases of non-IRIS-associated lymphoma and IRIS-associated lymphoma.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected
- hiv positive
- diffuse large b cell lymphoma
- hiv aids
- hiv infected patients
- hepatitis c virus
- end stage renal disease
- hiv testing
- free survival
- men who have sex with men
- oxidative stress
- ejection fraction
- risk factors
- chronic kidney disease
- prognostic factors
- south africa
- peritoneal dialysis